Christine M Kivlin, Kelsey L Watson, Ghadah A Al Sannaa, Roman Belousov, Davis R Ingram, Kai-Lieh Huang, Caitlin D May, Svetlana Bolshakov, Sharon M Landers, Azad Abul Kalam, John M Slopis, Ian E McCutcheon, Raphael E Pollock, Dina Lev, Alexander J Lazar, Keila E Torres
Poly (ADP) ribose polymerase (PARP) inhibitors, first evaluated nearly a decade ago, are primarily used in malignancies with known defects in DNA repair genes, such as alterations in breast cancer, early onset 1/2 (BRCA1/2). While no specific mutations in BRCA1/2 have been reported in malignant peripheral nerve sheath tumors (MPNSTs), MPNST cells could be effectively targeted with a PARP inhibitor to drive cells to synthetic lethality due to their complex karyotype and high level of inherent genomic instability...
2016: Cancer Biology & Therapy